Nektar Therapeutics is a biotechnology business based in the US. Nektar Therapeutics shares (NKTR.US) are listed on the NASDAQ and all prices are listed in US dollars. Its last market close was $1.38 – a decrease of 2.82% over the previous day. Nektar Therapeutics employs 137 staff and has a trailing 12-month revenue of around $90.1 million.
Only you can make the decision on the time to leap... but here's some supporting information and analysis.
Over the last 12 months, Nektar Therapeutics's shares have ranged in value from as little as $0.4126 up to $1.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nektar Therapeutics's is 0.912. This would suggest that Nektar Therapeutics's shares are less volatile than average (for this exchange).
Historical closes compared with the last close of $1.38
| 1 week (2024-04-17) | 4.55% |
|---|---|
| 1 month (2024-03-24) | 55.39% |
| 3 months (2024-01-24) | 170.59% |
| 6 months (2023-10-24) | 176.00% |
| 1 year (2023-04-24) | 76.92% |
| 2 years (2022-04-24) | -70.76% |
| 3 years (2021-04-22) | -92.99% |
| 5 years (2019-04-24) | -95.66% |
The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Nektar Therapeutics P/E ratio, PEG ratio and EBITDA
Nektar Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.22. Higher PEG ratios such as this can be interpreted as meaning the shares offer worse value given the current rate of growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Nektar Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.
A deep dive into the highlights and limitations of NinjaTrader.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
We rate robo-advisors across eight key categories, including ongoing costs, minimum deposit requirements, portfolio mix and more.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
SoFi is a commission-free platform with both active and automated investment accounts.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn how to buy physical gold and compare gold bullion dealers.
Take advantage of $0 trades and no investment minimums with this well-known broker.